Scienture Holdings (SCNX) investor relations material

Executive summary

• Focus shifted to specialty pharmaceuticals with the divestiture of legacy subsidiaries and acquisition of Scienture, LLC in July 2024, sharpening operational focus on branded and specialty pharma markets.

• Two commercial products launched: ARBLI™ (SCN-102, hypertension) and REZENOPY™ (SCN-110, opioid overdose), with three additional candidates in the pipeline targeting CNS and CVS diseases.

• Revenue growth driven by ARBLI™ launch, with sales concentrated among three major U.S. wholesale distributors.

Financial highlights

• Revenues for Q2 2026 were $343,639, up from $0 in Q2 2025; six-month revenues reached $399,964, up from $10,258 year-over-year.

• Gross profit for Q2 2026 was $335,779, with a gross margin of 97.7%.

• Net loss for Q2 2026 was $2,822,371, a 58% improvement from $6,720,573 in Q2 2025; six-month net loss was $6,224,635, down 36% year-over-year.

• Adjusted EBITDA for Q2 2026 was $(2,134,705), compared to $(2,263,734) in Q2 2025.

• Cash and cash equivalents as of June 30, 2026, were $8,188,140, with restricted cash of $3,012,271.

Outlook and guidance

• Management expects continued revenue growth from ARBLI™ and the launch of REZENOPY™ in Q3 2026.

• Existing cash, product revenues, and planned financing are expected to fund operations for at least 12 months.

• Ongoing focus on advancing pipeline candidates and exploring strategic business development opportunities.